LONG-TERM OUTCOMES WITH INITIAL TRIPLE ORAL THERAPY IN PULMONARY ARTERIAL HYPERTENSION (PAH): INSIGHTS FROM TRITON

被引：0

作者：

Howard, L. ^{[1
]}

Sitbon, O. ^{[2
]}

Galie, N. ^{[3
]}

Doelberg, M. ^{[4
]}

Gibbs, J. S. R. ^{[5
]}

Hoeper, M. M. ^{[6
,7
]}

Stefani, M. ^{[4
]}

Mathai, S. C. ^{[8
]}

McLaughlin, Vv ^{[9
]}

Perchenet, L. ^{[4
]}

Simonneau, G. ^{[2
]}

Chin, K. M. ^{[10
]}

机构：

[1] Hammersmith Hosp, London, England

[2] Univ Paris Sud, Hop Bicetre, Le Kremlin Bicetre, France

[3] Univ Bologna, Bologna, Italy

[4] Actel Pharmaceut Ltd, Allschwil, Switzerland

[5] Imperial Coll, Natl Heart & Lung Inst, London, England

[6] Hannover Med Sch, Hannover, Germany

[7] German Ctr Lung Res, Hannover, Germany

[8] Johns Hopkins Univ, Sch Med, Baltimore, MD USA

[9] Univ Michigan, Ann Arbor, MI 48109 USA

[10] UT Southwestern Med Ctr, Dallas, TX USA

来源：

THORAX | 2021年 / 76卷

关键词：

D O I：

10.1136/thorax-2020-BTSabstracts.99

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

S94

引用

页码：A57 / A57

页数：1

共 50 条

[1] Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON
Sitbon, Olivier
Galie, Nazzareno
Doelberg, Martin
Gibbs, J. Simon R.
Hoeper, Marius M.
Stefani, Mylene
Mathai, Stephen C.
Mclaughlin, Vallerie
Perchenet, Loic
Simonneau, Gerald
Chin, Kelly
EUROPEAN RESPIRATORY JOURNAL, 2020, 56
[2] Initial Triple Oral Therapy in Pulmonary Arterial Hypertension (PAH): Extended Long-Term Outcome Data from TRITON
McLaughlin, V.
Chin, K.
Doelberg, M.
Galie, N.
Hoeper, M. M.
Mathai, S. C.
Perchenet, L.
Simonneau, G.
Sitbon, O.
Martin, N.
Gibbs, J. S. R.
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2021, 40 (04): : S108 - S108
[3] Long-term outcomes in newly diagnosed pulmonary arterial hypertension (PAH) patients receiving initial triple oral combination therapy: insights from the randomised controlled TRITON study
Galie, N.
Sitbon, O.
Doelberg, M.
Gibbs, J. S. R.
Hoeper, M. M.
Martin, N.
Mathai, S. C.
McLaughlin, V
Perchenet, L.
Simonneau, G.
Chin, K.
EUROPEAN HEART JOURNAL, 2020, 41 : 2288 - 2288
[4] Impact of Initial Triple Combination Therapy on Long-Term Survival in Pulmonary Arterial Hypertension (PAH)
Boucly, A.
Savale, L.
Weatherald, J. C.
Montani, D.
Cottin, V.
Dauphin, C.
Picard, F.
Fard, D.
Mignard, X.
Jutant, E.
Jevnikar, M.
Jais, X.
Simonneau, G.
Humbert, M.
Sitbon, O.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
[5] Long-term sitaxsentan therapy in Pulmonary Arterial Hypertension (PAH)
Horn, E
Langleben, D
Frost, A
Hill, N
McLaughlin, V
Oudiz, R
Dixon, RAF
Barst, RJ
EUROPEAN HEART JOURNAL, 2004, 25 : 466 - 466
[6] Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
Calcaianu, George
Chaouat, Ari
Canuet, Matthieu
Kessler, Romain
EUROPEAN RESPIRATORY JOURNAL, 2015, 46
[7] Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
Calcaianu, George
Calcaianu, Mihaela
Canuet, Matthieu
Enache, Irina
Kessler, Romain
PULMONARY CIRCULATION, 2017, 7 (02) : 439 - 447
[8] Choice of Initial Oral Therapy for Pulmonary Arterial Hypertension: Age and Long-Term Survival
Heresi, Gustavo A.
Love, Thomas E.
Tonelli, Adriano R.
Highland, Kristin B.
Dweik, Raed A.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 198 (08) : 1090 - 1093
[9] Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
Peter Steele
Geoff Strange
John Wlodarczyk
Brad Dalton
Simon Stewart
Eli Gabbay
Anne Keogh
BMC Cardiovascular Disorders, 10
[10] Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
Steele, Peter
Strange, Geoff
Wlodarczyk, John
Dalton, Brad
Stewart, Simon
Gabbay, Eli
Keogh, Anne
BMC CARDIOVASCULAR DISORDERS, 2010, 10

← 1 2 3 4 5 →